India's Wockhardt Ltd. has received qualified infectious disease product (QIDP) status from the US Food and Drug Administration (FDA) for its zidebactam-based combination antibiotic WCK 6777 to treat complicated urinary tract infections and complicated intra-abdominal infections, taking to six the total number of its products with this special designation.
The agency grants QIDP status to drugs effective against a set of multi-drug resistant pathogens identified by the Centers for...








